CD34 and acute myeloid leukemia: Additional studies will be necessary to test whether similar principles regarding CD34+ and CD3+ cell doses apply for other donor cell scenarios, and what other graft cell components might impact outcomes in AML patients receiving HLA-matched donor cells.